Mohit Manrao: The results of AstraZeneca’s CAPItello-281 Phase III trial
Mohit Manrao, SVP and Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“This post is intended for a U.S. audience.
The results of AstraZeneca’s CAPItello-281 Phase III trial offer new hope for patients with metastatic hormone-sensitive prostate cancer (mHSPC), an aggressive form of the disease with an urgent level of unmet need.
The data show this combination therapy demonstrated a statistically significant and clinically meaningful improvement versus abiraterone and ADT with placebo.
This news marks the first time an AKT-inhibitor combination has demonstrated clinical benefit in this specific subtype of prostate cancer.
Prostate cancer is the second most diagnosed cancer in men and the fifth leading cause of cancer death in men globally. Men with metastatic PTEN-deficient HSPC face a poor prognosis, highlighting a pressing need for new treatments.
I congratulate our teams on their outstanding work. Their passion and dedication have brought us closer to new prostate cancer treatments that improve patients’ lives.
Read more in the press release.”
Proceed to the video attached to the post.
More posts featuring Mohit Manrao.
Mohit Manrao is the SVP and Head of US Oncology at AstraZeneca and President of the AstraZeneca Foundation, where he leads community grant programs. As Executive Sponsor of AstraZeneca’s US Health Equity Initiative, he focuses on reducing healthcare disparities. He also serves as a Board Member of the National Pharmaceutical Council.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023